Loading…
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-235M | $-247M | $-199M | -59.5% | - | 14.6% |
| 2024 | $0M | $-206M | $-216M | $-191M | -57.6% | - | 23.8% |
| 2023 | $0M | $-167M | $-174M | $-130M | -31.4% | - | 47.7% |
| 2022 | $0M | $-114M | $-118M | $-85M | -28.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 115.14 | 174.17 | 232.85 | 259.85 |
| Research And Development | 79.54 | 126.53 | 174.96 | 189.45 |
| Selling General And Administration | 38.77 | 50.55 | 59.81 | 72.18 |
| Total Expenses | 115.14 | 174.17 | 232.85 | 259.85 |
| Operating Income | -115.14 | -174.17 | -232.85 | -259.85 |
| Total Operating Income As Reported | -118.31 | -177.08 | -234.77 | -261.63 |
| EBITDA | -113.67 | -167.39 | -206.07 | -235.43 |
| Normalized EBITDA | -114.06 | -177.40 | -229.43 | -256.55 |
| EBIT | -115.81 | -169.84 | -208.73 | -238.94 |
| Interest Expense | 2.22 | 4.16 | 6.66 | 7.89 |
| Net Interest Income | -2.22 | -4.16 | -6.66 | -7.89 |
| Other Non Operating Income Expenses | -1.06 | -5.68 | 0.77 | -0.20 |
| Other Income Expense | -0.67 | 4.33 | 24.13 | 20.92 |
| Interest Expense Non Operating | 2.22 | 4.16 | 6.66 | 7.89 |
| Net Non Operating Interest Income Expense | -2.22 | -4.16 | -6.66 | -7.89 |
| Pretax Income | -118.04 | -174 | -215.39 | -246.83 |
| Tax Provision | 0 | 0.29 | 0.41 | 0.47 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0.02 | 4.90 | 4.44 |
| Net Income Continuous Operations | -118.04 | -174.28 | -215.79 | -247.30 |
| Net Income From Continuing And Discontinued Operation | -118.04 | -174.28 | -215.79 | -247.30 |
| Net Income From Continuing Operation Net Minority Interest | -118.04 | -174.28 | -215.79 | -247.30 |
| Net Income | -118.04 | -174.28 | -215.79 | -247.30 |
| Net Income Common Stockholders | -118.04 | -174.28 | -215.79 | -247.30 |
| Net Income Including Noncontrolling Interests | -118.04 | -174.28 | -215.79 | -247.30 |
| Normalized Income | -118.43 | -184.27 | -234.25 | -263.98 |
| Diluted NI Availto Com Stockholders | -118.04 | -174.28 | -215.79 | -247.30 |
| Basic Average Shares | 52.21 | 58.21 | 66.57 | 80.56 |
| Diluted Average Shares | 52.21 | 58.21 | 66.57 | 80.56 |
| Reconciled Depreciation | 2.15 | 2.45 | 2.66 | 3.50 |
| Total Unusual Items | 0.39 | 10.01 | 23.36 | 21.12 |
| Total Unusual Items Excluding Goodwill | 0.39 | 10.01 | 23.36 | 21.12 |
| Special Income Charges | 0 | - | - | - |
| Gain On Sale Of Security | 0.39 | 10.01 | 23.36 | 21.12 |
| Other Operating Expenses | -3.17 | -2.91 | -1.92 | -1.77 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Replimune Group, Inc.this co. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Janux Therapeutics, Inc. | JANX | $839M | -7.39 | 0.88 | -11.9% | -5.20 |
| ORIC Pharmaceuticals, Inc. | ORIC | $830M | -6.41 | 2.16 | -33.7% | -5.56 |
| LB Pharmaceuticals Inc | LBRX | $829M | -32.88 | 2.75 | -8.4% | -19.35 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M |
| 8.41 |
| 1.05 |
| 12.4% |
| 6.17 |
| Sana Biotechnology, Inc. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Esperion Therapeutics, Inc. | ESPR | $806M | - | - | 7.5% | 13.94 |
| Lumexa Imaging Holdings, Inc. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Eton Pharmaceuticals, Inc. | ETON | $792M | -172.06 | 30.27 | -17.6% | 248.97 |
| Peer Median | - | -7.39 | 2.16 | -10.1% | 0.93 | |